Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

Phase 2 Completed 299 enrolled Resverlogix Corp

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate dose range, safety and efficacy of RVX000222 in subjects with stable coronary artery disease.

Timeline

Start: 2009-12
Primary completion: 2010-06
Completion: 2010-09

Outcome

Missed primary endpoint

paper individual pairwise comparisons of apoA-I changes with placebo, the primary end point, did not achieve statistical significance. PMID 21255957 ↗

Publications

Nicholls SJ, Gordon A, Johansson J, Wolski K, Ballantyne CM, Kastelein JJ, Taylor A, Borgman M, Nissen SE. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011 Mar 1;57(9):1111-9. doi: 10.1016/j.jacc.2010.11.015. Epub 2011 Jan 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apabetalone	Small molecule	50 mg	Oral
Subject	Apabetalone	Small molecule	100 mg	Oral
Subject	Apabetalone	Small molecule	150 mg	Oral